MedinCell S.A. Profile Avatar - Palmy Investing

MedinCell S.A.

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceuti…

Biotechnology
FR, Jacou [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
MedinCell S.A. can't present any analysts estimates at the moment detail analysis.
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
MedinCell S.A. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$16.80
End of MEDCL.PA's Analysis
CIK: - CUSIP: F6104D107 ISIN: FR0004065605 LEI: - UEI: -
Secondary Listings
MEDCL.PA has no secondary listings inside our databases.